Quinn Opportunity Partners’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Quinn Opportunity Partners’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-58,227	Closed	-$559K	–	472
2024 Q4	$559K	Buy	+58,227	New	+$304K	0.04%	252

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Quinn Opportunity Partners's PSTX Position: Q1 2025 in Review

Quinn Opportunity Partners sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 58,227 shares — an estimated $559K sold.

Quinn Opportunity Partners first reported a position in PSTX in Q4 2024 and held it in 1 quarter. The position peaked at $559K in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

Quinn Opportunity Partners reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Quinn Opportunity Partners sold 58,227 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $559K.
Quinn Opportunity Partners first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2024 and held it in 1 quarter.
Quinn Opportunity Partners's Poseida Therapeutics, Inc. Common Stock position peaked at $559K in Q4 2024.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Quinn Opportunity Partners's 13F filing for Q1 2025, filed 14 May 2025.